Timothy FitzSimons is a member of the firm's Corporate Department. His practice focuses on public and private mergers and acquisitions with an emphasis on friendly and unsolicited tender offers and advising independent directors in conflict of interest transactions, financial sponsor and portfolio company representation in private equity and venture capital transactions and public company representation.
Mr. FitzSimons co-authored “Designatting Delaware as the Exclusive Jurisdiction for Intra-Corporate Disputes: A New “Must” for Delaware Company Charter or Bylaws” and “A Roadmap of Recent Regulatory Action for the M&A Practitioner.”
Mr. FitzSimons has served in a management role at the firm as a member of the Global Recruiting Committee and is also a member of the Chicago Bar Association and the Illinois Bar Association.
In recent transactions, Mr. FitzSimons has advised both buyers and sellers in mergers and acquisitions, including:
- The Special Committee of the Board of Directors of Genentech, Inc., in its US$46.8 billion merger with Roche Holdings, Inc., pursuant to a tender offer
- Eli Lilly and Company in its US$6.5 billion tender offer for ImClone Systems Incorporated
- The Special Committee of the Board of Directors of CBOT Holdings, Inc., in its US$12 billion merger with Chicago Mercantile Exchange Holdings, Inc.
- Nicor Inc. in its US$3.1 billion merger with AGL Resources Inc.
- Ericsson in its US$2.1 billion tender offer for Redback Networks Inc.
- Orbitz, Inc., in its sale pursuant to a US$1.2 billion tender offer by Cendant Corporation
- Safeco Corporation in the US$1.35 billion sale of its Life and Investments business to White Mountain Insurance Group, Ltd.
- Axcan Pharma Inc., (n/k/a Aptalis) in an unsolicited tender offer and proxy contest for Salix Pharmaceuticals, Inc.
Mr. FitzSimons has also represented private equity and venture capital investors and portfolio companies in financing and general company representation matters.